MiNK Therapeutics, Inc.
NASDAQ:INKTBiotechnology
-$0.35 today
- Market cap
- $52.17M
- Beta
- 0.47
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.60
Volume 0.01M
Average 0.05M
Returns on capital
MiNK Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
87.8%
avg 1030.1%
ROIC
-195.5%
avg 149.3%
ROA
-87.7%
avg -450.0%
Analysis
ROE is currently the strongest return metric at 87.8% versus its period average of 1030.1%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Jennifer S. Buell | Co-Founder, President, CEO & Director | USD 803.69K | 51 | — | — |
Garo H. Armen | Executive Chairman | — | 73 | 0 | <0.01% |
Marco Purbhoo | Head of Translational Medicine | — | — | — | — |
Terese C. Hammond | Head of Inflammatory & Pulmonary Diseases | — | — | — | — |
Melissa Orilall | Principal Financial Officer | — | 37 | 222 | <0.01% |
Austin Charette | Principal Accounting Officer | — | 37 | 40 | <0.01% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 13, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
9
$119,884.19
Net Transaction Value
−$119,884.19
Net selling
Most Active
Ryan Barbara
8 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 12, 26Oct 12, 2026 | Buell Jennifer Direct | Sell | $73.3K$73,265.28 |
| Jun 4, 26Jun 4, 2026 | Ryan Barbara Direct | Sell | $6.3K$6,341.75 |
| Jun 4, 26Jun 4, 2026 | Ryan Barbara Direct | Sell | $12.8K$12,799.50 |
| Mar 10, 26Mar 10, 2026 | Ryan Barbara Direct | Sell | $7.7K$7,650.00 |
| Mar 10, 26Mar 10, 2026 | Ryan Barbara Direct | Sell | $4.6K$4,584.66 |
| Mar 10, 26Mar 10, 2026 | Ryan Barbara Direct | Sell | $7.8K$7,782.60 |
| Mar 9, 26Mar 9, 2026 | Ryan Barbara Direct | Sell | $2K$2,034.50 |
| Mar 2, 26Mar 2, 2026 | Ryan Barbara Direct | Sell | $1.1K$1,082.58 |
| Feb 27, 26Feb 27, 2026 | Ryan Barbara Direct | Sell | $4.3K$4,343.32 |
Summary
Insiders reported 0 buys worth $0.00 and 9 sells worth $119,884.19 over the last 12 months. That adds up to net selling of $119,884.19. Ryan Barbara was the most active insider with 8 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does MiNK Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about INKT's management, answered from reported figures.
Who manages INKT?
MiNK Therapeutics, Inc. (INKT) lists 6 active executives. The top listed executive is Garo H. Armen, Executive Chairman.
Are INKT insiders buying or selling?
Recent insider activity shows net buying of $19.98M.
Continue the stock analysis
Jump to another research area for this company.